Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis
Author:
Affiliation:
1. Department of Respiratory and Critical Care Medicine, West China Hospital Sichuan University Chengdu China
2. Department of Neurosurgery Suining Municipal Hospital of TCM Suining China
Funder
National Natural Science Foundation of China
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15155
Reference76 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice guideline update;Kalemkerian GP;J Clin Oncol,2018
3. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
4. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets
5. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The safety and efficacy of binimetinib for lung cancer: a systematic review;BMC Pulmonary Medicine;2024-08-01
2. Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy;British Journal of Clinical Pharmacology;2024-07-30
3. Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment;Clinical and Translational Oncology;2024-05-25
4. HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies;Life;2023-12-29
5. Efficacy and safety of a pyrotinib-based regimen in non-small cell lung cancer patients harboring HER2 alterations: A real-world retrospective study;Journal of Cancer Research and Therapeutics;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3